Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2017-11-01

Clinical Trial Update: Drug/Drug Interactions With F901318 [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing drug interactions with F901318 in invasive aspergillosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • F901318

Snippet

Sponsor: F2G Biotech GmbH | Conditions: Invasive Aspergillosis | Phase 1 | Status: WITHDRAWN